中國創新投資(01217.HK)向心及龔青涉台共諜案獲確定全案不起訴
中國創新投資(01217.HK)公布,關於執行董事兼行政總裁向心及其替任董事龔青在台所涉「共諜」案,歷經台北地檢署兩度不起訴,台灣高等檢察署自為偵查之後,昨日宣布確定全案不起訴,讓他們擺脫滯台1,363天的「共諜」之名。
北檢偵查期間,曾向澳洲提出司法互助未果,也查無向心夫婦其餘事證,於2021年11月12日將向心及龔青首次處分不起訴。全案經台高檢再議之後,將向心及龔青發回續查。北檢續查一年之後,仍於今年5月10日二度處分不起訴。此後台高檢自為偵查,之後終在今年8月17日確定不起訴。
另北檢起訴向心夫妻涉嫌「洗錢」,一審台北地院判決無罪,二審高等法院已定2023年9月6日宣判。向心及龔青目前暫時未能離境。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.